Skip to main content
OpenTrials
Completed

NCT Number: NCT02211885

Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects

Study to characterize the pharmacokinetics of 14C-radiolabeled BIRB 796 BS and its metabolites including excretion and mass balance of parent compound and radioactivity; to isolate, identify and quantify major radiolabeled metabolites of BIRB 796 in plasma, urine and feces

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects as determined by results of screening. Health is confirmed by medical history, physical examination, laboratory testing and 12-lead electrocardiogram (ECG)
  • Signed written informed consent in accordance with Good Clinical Practice
  • Age ≥ 18 and ≤ 45 years
  • Subjects within 10% of the normal height: weight range defined by the Metropolitan Life Insurance Company Tables

Exclusion criteria

  • Any finding of the medical examination (including blood pressure, pulse rate, and ECG) deviating from normal and of clinical relevance
  • History of clinically significant disease including metabolic, endocrinologic, immunological, hepatic, renal, gastrointestinal, respiratory, cardiovascular, psychiatric or neurological
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Subjects with a history of drug abuse or alcoholism
  • Chronic or relevant acute (within 1 month of screening) infections
  • Subjects who have taken prescription within one month or over-the-counter drugs within two weeks of the start of the trial
  • Participation in another trial with an investigational drug (≤ 2 months prior to administration or during trial)
  • Inability to refrain from smoking on trial days
  • Blood donation > 400 mL (within 1 month prior to administration or during the trial)
  • Any laboratory value outside 10% of the reference range of clinical relevance (but not exclusive to) total white cell count ≥ 10 x 10**9/L, any hemoglobin < 12 mg/dl or >15 mg/dl. Protein on urine dipstick
  • Positive urine drug screen, positive HIV or Hepatitis C antibodies
  • History of any familial bleeding disorder

Treatment and study plan

14C-BIRB 796 BS

Drug

14C-radiolabeled BIRB 796 BS

Primary outcomes

  1. Cumulative amount of 14C-BIRB 796 BS radioactivity excreted in feces (percent of dose)

    Time frame: up to 5 days

  2. Cumulative amount of 14C-BIRB 796 BS radioactivity excreted in urine (percent of dose)

    Time frame: up to 5 days

  3. Maximum observed Concentration (Cmax) of 14C-BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  4. Area under the Concentration versus time curve from time 0 to infinity (AUC0-∞) of 14C-BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  5. Time To The Maximum Concentration (tmax) of 14C-BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  6. Elimination Half-Life (t1/2) of 14C-BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  7. Erythrocyte-plasma partition ratio of 14C-radioactivity

    Time frame: up to 5 days

  8. Cmax of 14C-BIRB 796BS in blood

    Time frame: up to 96 hours after drug administration

  9. AUC0-∞ of 14C-BIRB 796BS in blood

    Time frame: up to 96 hours after drug administration

  10. tmax of 14C-BIRB 796BS in blood

    Time frame: up to 96 hours after drug administration

  11. t1/2 of 14C-BIRB 796BS in blood

    Time frame: up to 96 hours after drug administration

  12. Cmax of BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  13. AUC0-∞ of BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  14. tmax of BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  15. t1/2 of BIRB 796BS in plasma

    Time frame: up to 96 hours after drug administration

  16. Quantification of radiolabeled metabolites in urine (percent of dose)

    Time frame: up to 5 days

  17. Quantification of radiolabeled metabolites in feces (percent of dose)

    Time frame: up to 5 days

  18. Quantification of radiolabeled metabolites in plasma (percent of dose)

    Time frame: up to 96 hours after drug administration

Secondary outcomes

  1. Excretion of 14C-radioactivity in saliva (percent of dose)

    Time frame: up to 24 hours after drug administration

  2. Excretion of 14C-radioactivity in expired air (percent of dose)

    Time frame: up to 48 hours after drug administration

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Phase I Single Oral Dose (100 mg) Trial to Characterize the Excretion Balance of 14c-radiolabeled BIRB 796 BS and to Determine Its Metabolites in Normal Male Subjects

Important dates

Study start
2002
Primary completion
2002
First posted
Aug 8, 2014
Registry last updated
Aug 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.